Advertisement

Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

María-Victoria Mateos, Norma C. Gutiérrez, María-Luisa Martín-Ramos, Bruno Paiva, María-Angeles Montalbán, Albert Oriol, Joaquín Martínez-López, Ana-Isabel Teruel, Enrique Bengoechea, Alejandro Martín, Joaquín Díaz-Mediavilla, Felipe de Arriba, Luis Palomera, José-Mariano Hernández, Anna Sureda, Joan Bargay, Francisco-Javier Peñalver, Josep-Maria Ribera, María-Luisa Martín-Mateos, Manuela Fernández, Ramón García-Sanz, María-Belén Vidriales, Joan Bladé, Juan-José Lahuerta and Jesús F. San Miguel

Article Figures & Data

Figures

Tables

  • Table 1

    Baseline characteristics according to cytogenetic abnormalities

    Standard-risk (n = 188)High-risk* (n = 44)P
    Age, y (range)72 (65-85)72 (66-83)NS
    Hemoglobin, g/dL, mean10.89.6NS
    Calcium, mg/dL, mean9.69.5NS
    Creatinine, mg/dL, mean1.021.0NS
    B2-microglobulin, mg/L, mean3.85.2NS
    PCs BM infiltration, %, mean3844NS
    S-phase of PCs, %1.51.5NS
    ISS stage, %
        I2816
        II4241NS
        III3043
    Induction regimen, %
        VMP/VTP49/5150/50NS
    Maintenance regimen, %
        VT/VP51/4954/46NS
    • ISS indicates International Staging System; and PCs, plasma cells.

    • * Forty-four of these 232 patients qualified as high-risk (19%); 17 of them (7%) had t(4;14) ± del(13q), 21 patients (9%) had del(17p) ± del(13q), in 3 cases (1%) t(4;14) and del(17p) coexisted, and 3 additional patients (1%) had t(14;16). Only 1 patient had t(4;14) as single CA.

  • Table 2

    Best response during induction and maintenance therapy according to cytogenetic abnormalities

    Standard-risk (n = 188)High-risk (n = 44)P
    After induction therapy with VMP/VTP
        IF CR27%21%NS
        IF+ CR10%11%NS
        PR45%47%NS
    After maintenance therapy with VT/VP
        IF CR45%40%NS
        IF+ CR13%11%NS
        PR38%50%NS
    • PR indicates partial response.

  • Table 3

    Baseline characteristics according to DNA ploidy

    Hyperdiploid (n = 132)Non-hyperdiploid (n = 92)P
    Age, y (range)73 (65-85)73 (65-84)NS
    Hemoglobin, g/dL, mean10.810.5NS
    Calcium, mg/dL, mean9.69.6NS
    Creatinine, mg/dL, mean1.041.03NS
    B2-microglobulin, mg/L, mean3.94.9NS
    PCs BM infiltration, %, mean3743NS
    S-phase of PCs, %1.61.3NS
    ISS stage, %
        I3022
        II3945NS
        III3134
    Induction regimen, %
        VMP/VTP51/4952/48NS
    Maintenance regimen, %
        VT/VP52/4849/50NS
    • ISS indicates International Staging System; and PCs, plasma cells.

  • Table 4

    Best response during induction and maintenance therapy according to DNA ploidy

    Hyperdiploid (n = 132)Non-hyperdiploid (n = 92)P
    After induction therapy with VMP/VTP
        IF CR23%25%NS
        IF+ CR9%13%NS
        PR51%40%NS
    After maintenance therapy with VT/VP
        IF CR43%41%NS
        IF+ CR13%14%NS
        PR41%40%NS
    • PR indicates partial response.